Next generation kinase inhibitors
with unique properties
Potent and selective Nanocyclix leads for known
and novel kinases.
New partnering opportunity: Nanocyclix RIPK2 inhibitors
for use in auto-immune diseases
Pave the way for a truly personalized approach in cancer.
Translational biomarker approaches
to address patient needs
Pharmaco-imaging in support of therapeutic development
and for drug targeting.
State-of-the-art models for optimal
Patient-derived xenografts and human immune system
models to allow better decisions.
We partner to advance cancer
Joining forces to the benefits of patients.
A large panel of technological and scientific solutions for pharmacological qualification of your compounds : a unique oncology preclinical CRO
A platform-based approach for the discovery of novel chemical entities with therapeutic and diagnostic potential